![Fmoc-L-Lys[C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA]-OH](/upload/2026/7/89-1.jpg "Fmoc-L-Lys[C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA]-OH")
2026/09/10
Daraxonrasib (RMC-6236): Molecular Design Behind Multi-Selective RAS Recognition Daraxonrasib, formerly known as RMC-6236 , has drawn attention for a design strategy that differs from many earli...
2026/09/10
Daraxonrasib (RMC-6236): RAS(ON) Chemistry and Process Development Daraxonrasib, previously known as RMC-6236 , is a RAS(ON) multi-selective inhibitor designed to engage active, GTP-bound RAS....
2026/09/04
From R&D to Scale-Up: How Shandong Juntai Supports Pharmaceutical Intermediate and Peptide-Related Projects Moving a pharmaceutical intermediate or peptide-related project from laboratory dev...
2026/09/04
When researching Semaglutide side-chain intermediates , CAS 1662688-20-1, 1118767-16-0 and 1169630-40-3 often appear in the same product category. All three are associated with the lipid side-chain ...
2026/08/12
AEEA-AEEA (CAS 1143516-05-5) Supply Capability and Manufacturing Support for Peptide Research Applications Meta Description Shandong Juntai Pharmaceutical provides AEEA-AEEA (CAS 1143516-05-5), a...
2026/07/08
In June 2026, CPHI China 2026, the highly anticipated annual grand event of the global pharmaceutical industry, concluded with great success at the Shanghai New International Expo Centre. On this gra...
